Status:
COMPLETED
Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Kenya Medical Research Institute
Conditions:
HIV Infections
Acquired Immunodeficiency Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Both antiretroviral therapy (ART) and prevention of opportunistic infections (OIs) have been associated with significantly decreased mortality in HIV-infected individuals. Trimethoprim-sulfamethoxazol...
Detailed Description
Please see summary above.
Eligibility Criteria
Inclusion
- Participants must be at least 18 years of age.
- Participants must be willing to participate and give written informed consent.
- Participants must be willing and able to return for the scheduled follow-up visits.
- Participants must have been on ART for \> 18 months.
- Participants must have a CD4 count of \> 350 cells/mm3.
- Participants must not be suspected of ART treatment failure.
Exclusion
- Participants must not be pregnant at enrollment (by urine HCG testing).
- Participants must not be breastfeeding at the time of enrollment.
- Participants must be on first-line ART therapy as defined by Kenyan National Guidelines.
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01425073
Start Date
February 1 2012
End Date
October 1 2013
Last Update
April 11 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Homa Bay District Hospital
Homa Bay, Nyanza Pronvince, Kenya
2
Kombewa District Hospital
Kombewa, Nyanza, Kenya